
Paula Marcela Cuéllar-Pinzón, MD, María Paula Montes-Lozano, MD, Marco Antonio Suárez-Fuentes, MD, Miller Jesús Melo-Mora, MD and Michael Gregorio Ortega-Sierra, MD*

1School of Medicine, Fundación Universitaria Sanitas, Bogota, Colombia  
2School of Medicine, Universidad Metropolitana, Barranquilla, Colombia  
3School of Medicine, Universidad del Sinú, Cartagena, Colombia  
4School of Medicine, Escuela Latinoamericana de Medicina en Cuba, La Habana, Colombia  
5School of Medicine, Corporación Universitaria Rafael Nuñez, Cartagena, Colombia

*Corresponding author: Michael Gregorio Ortega-Sierra, School of Medicine, Corporación Universitaria Rafael Nuñez, Cartagena, 130004, Colombia

Keywords  
Coronary disease, COVID-19, Post-COVID-19 cardiovascular syndrome, Post-COVID-19 syndrome, Cardiac imaging techniques

The COVID-19 pandemic has generated numerous questions about the pathophysiology of the acute phase of this disease, and as time goes by, also of the chronic phase, known as post-COVID-19 syndrome [1-4]. Although the neurological phenotype (post-COVID-19 neurological syndrome) is the most debated [1,2], the evidence points to the fact that the main manifestations of post-COVID-19 patients, regardless of disease severity, are dyspnea, fatigue, tachycardia, and difficulties in performing activities of daily living [5]. This raises alarms about the presence of persistent target organ injury since the acute phase of COVID-19, or whether previous inflammation may have uncompensated the mechanisms that some organs perform in the face of chronic disorders. There is evidence that has reported the compromise of the endothelium and myocardium during the acute phase of the disease, with the presence of previous heart disease being considered a risk factor for severe disease and death [6].

Interestingly, Drakos, et al. [7] evaluated coronary microvascular disease in COVID-19 patients by cardiovascular magnetic resonance imaging, showing that patients who had COVID-19 had significantly reduced global myocardial perfusion reserve (2.73 [2.10 - 4.15 - 11] vs. 4.82 [3.70-6.68], p = 0.005), significantly increased coronary sinus flow at rest (1.78 ml/min [1.19-2.23 ml/min] vs. 1.14 ml/min [0.91-1.32 ml/min], p = 0.048), and reduced coronary sinus flow during stress activity (3.33 ml/min [2.76-4.20 ml/min] vs. 5.32 ml/min [3.66-5.52 ml/min], p = 0.05), compared to controls [7]. Based on the above, the authors concluded that there is cardiac microvascular injury in COVID-19 patients, which may trigger major cardiovascular events in the post-COVID-19 phase, and this is one of the reasons that would explain the persistence of fatigue and dyspnea during this phase [7].

Another study that supports the persistence of endothelial dysfunction, but using another vascular parameter (flow-mediated dilation), is that of Ambrosino, et al. [8], who carried out a case-control study with 133 patients where they found that a significantly lower flow-mediated dilation in post-COVID 19 patients as compared to controls (3.2% ± 2.6
vs. 6.4% ± 4.1 p < 0.001), confirmed when stratifying the study population according to age and major clinical variables. Among cases, females exhibited significantly higher flow-mediated dilation values as compared to males (6.1% ± 2.9 vs. 2.5% ± 1.9, p < 0.001). Among post-COVID 19 patients, flow-mediated dilation showed a direct correlation with arterial oxygen tension (0.247, p = 0.004), forced expiratory volume in 1s (0.436, p < 0.001), forced vital capacity (0.406, p < 0.001), and diffusing capacity for carbon monoxide (0.280, p = 0.008). In conclusion, post-COVID-19 syndrome was a major and independent predictor of flow-mediated dilation values (β = -0.427, p < 0.001) [8]. This allows us to understand that although the study investigated pulmonary vascular dynamics and some respiratory parameters, the endothelial damage could be the same and can be correlated with the mechanism of lung-heart circulation [7-9].

It is valid then, even to raise the question of whether there is silent myocarditis in the patient with asymptomatic COVID-19, which through compensatory mechanisms does not develop symptoms, but leaves a trace in the vascular and cardiac territory? clearly, in the patient with cardiovascular risk factors, we should inquire more quickly through translational research on the degree of tissue inflammation or activation of profibrogenic or proatherogenic signaling pathways, which alter cardiac dynamics [10].

This should force the general practitioner and the cardiologist to ask themselves, what is the status of the patient with a history of cardiovascular disease who is in the post-COVID-19 phase, regardless of the presence of symptoms or not? The history of ischemic heart disease, heart failure (especially with reduced ejection fraction) or any other condition that may generate hemodynamic or metabolic alterations such as hypertension or diabetes mellitus [3,10], should be interpreted in clinical practice as warning signs in the patient with possible impairment of functional capacity and survival due to a possible major cardiovascular event during the post-COVID phase [5-9].

From this, lies the importance of using cardio-imaging such as cardiovascular magnetic resonance imaging, which allows an accurate, broad and deep evaluation of cardiac functionality and structure, and provides information on the suggestive existence or absence of myocardial compromise secondary to COVID-19 [7-9], which may decrease the functional capacity of the individual, increase the risk of decompensation (for example in the patient with heart failure) or death, or re-evaluate therapeutic plans based on the findings and the mechanisms of action of the most appropriate drugs for each case. Prospective multicenter studies are needed to define cutoff scores for hemodynamic and structural parameters to control the burden of cardiovascular disease that is expected in this group of patients.

Funding

None.

Conflicts of Interest

None.

References